SEC Form 4 · accession 0001193125-26-277766
Kymera Therapeutics, Inc. · KYMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Noah Goodman
Officer — Chief Business Officer
Period of report
Jun 22, 2026
Accepted (ET)
Jun 22, 2026 · 5:47 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001815442
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 22, 2026 | M | 2,500 | $21.05 | A | 52,695 | D | |
| Common Stock | Jun 22, 2026 | S | 2,500 | $99.00 | D | 50,195 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $21.05 | Jun 22, 2026 | M | 2,500 | D | — | Apr 7, 2035 | Common Stock | 2,500 | 95,000 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
- F2Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.